Hemanext Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System
Product now available in Norway, Blood centers in Italy, Switzerland, and
France expected to complete validations later this year
LEXINGTON, Mass., April 13, 2021 /PRNewswire/ Hemanext Inc., a privately held medical technology company, today announced it has received a CE Certificate of Conformity for the CE Mark for its Hemanext ONE Red Blood Cell (RBC) Processing and Storage System, allowing the innovative medical device to be sold in European markets. Blood center validations required for the adoption of the Hemanext ONE RBC Processing and Storage System were completed in Norway in 2020. The company expects blood centers in Italy, Switzerland, and France to complete validations in 2021. Hemanext plans to secure additional validations and approvals in order to make the device available to healthcare professionals in other select European markets and in the Americas i
Kristin Novotny once led an active life, with regular CrossFit workouts and football in the front yard with her children — plus a job managing the kitchen at a middle
Published: Apr 13, 2021
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE)
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet’s research group and will further develop existing and new opportunities for the Company’s gamma delta T cell platform.
“We are very excited to have Blake join Adicet, and lead our research team as we advance the clinical development of ADI-001 and rapidly develop a deep pipeline of “off-the-shelf” gamma delta T cell therapies,” said Stewart Abbot, Chief Scientific and Operating Officer of Adicet. “Blake has committed his career, with notable success, to researching and developing cell therapies across a variety of indications including oncology, infectious disease, and autoimmune conditions, while also buildin
Amoeba Biology Reveals Potential Treatment Target for Lung Disease
Illustration of cilia and surface hydration among normal airway cells and those affected by cigarette smoke.
Newswise In a series of experiments that began with amoebas single-celled organisms that extend podlike appendages to move around Johns Hopkins Medicine scientists say they have identified a genetic pathway that could be activated to help sweep out mucus from the lungs of people with chronic obstructive pulmonary disease a widespread lung ailment.
“Physician-scientists and fundamental biologists worked together to understand a problem at the root of a major human illness, and the problem, as often happens, relates to the core biology of cells,” says Doug Robinson, Ph.D., professor of cell biology, pharmacology and molecular sciences, medicine (pulmonary division), oncology, and chemical and biomedical engineering at the Johns Hopkins University School of Medicine.